Tatsuya Atsumi

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

Spiros Miyakis, Michael D. Lockshin, Tatsuya Atsumi et al. · Journal of Thrombosis and Haemostasis · 2006 · 7.1K citations · Full text

Medicine, Hematology, Internal Medicine +10

Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial

Dinesh Khanna, Celia J. F. Lin, Daniel E. Furst et al. · The Lancet Respiratory Medicine · 2020 · 652 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +4

The 2023 <scp>ACR</scp>/<scp>EULAR</scp> Antiphospholipid Syndrome Classification Criteria

Medha Barbhaiya, Stéphane Zuily, Ray Naden et al. · Arthritis & Rheumatology · 2023 · 431 citations · Full text

Medicine, Internal Medicine, Autoimmunity +15

2023 ACR/EULAR antiphospholipid syndrome classification criteria

Medha Barbhaiya, Stéphane Zuily, Ray Naden et al. · Annals of the Rheumatic Diseases · 2023 · 424 citations · Full text

Life Sciences, Hematology, Internal Medicine +17

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

Désirée van der Heijde, James Cheng‐Chung Wei, Maxime Dougados et al. · The Lancet · 2018 · 359 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +14